Health
Cutting edge synthetic peptides block SARS-CoV-2 (COVID-19) – News-Medical.Net
Researchers at Ligandal Inc., the University of California San Francisco and Toyota Technological Institute at Chicago, have designed novel synthetic peptides that potently inhibit the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to…
Researchers at Ligandal Inc., the University of California San Francisco and Toyota Technological Institute at Chicago, have designed novel synthetic peptides that potently inhibit the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells.
The team’s SARS-BLOCK™ peptides competitively inhibit the receptor-binding domain (RBD) on the SARS-CoV-2 spike protein – the surface structure that binds the host cell angiotensin-converting enzyme 2 (ACE2) receptor, to…
-
Noosa News15 hours agoMan dies in Brisbane crash, women and girl rushed to hospital
-
Noosa News21 hours agoChilling new details emerge in terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
Business20 hours agoAre BHP shares are buy after its results?
-
Business12 hours agoWhere next for the CBA share price?